HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PM226

a selective CB2 receptor agonist with neuroprotective profile; structure in first source

Also Known As:

7-(1,1-dimethylheptyl)-4,4-dimethyl-9-methoxychromeno(3,4-d)isoxazole

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - PM226: 2

Experts

1.	Carrillo-Salinas, Francisco J: 1 article (01/2016)
2.	Fernández-Ruiz, Javier: 1 article (01/2016)
3.	Franco, Rafael: 1 article (01/2016)
4.	Goya, Pilar: 1 article (01/2016)
5.	Guaza, Carmen: 1 article (01/2016)
6.	Gómez-Cañas, María: 1 article (01/2016)
7.	Hurst, Dow P: 1 article (01/2016)
8.	Jagerovic, Nadine: 1 article (01/2016)
9.	Lagartera, Laura: 1 article (01/2016)
10.	Morales, Paula: 1 article (01/2016)

Related Diseases

1.	Chronic Progressive Multiple Sclerosis 01/01/2016 - "The most promising compound [43 (PM226)], a selective and potent CB2 agonist isoxazole derivative, was tested in the acute phase of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a well-established animal model of primary progressive multiple sclerosis. "
2.	Hyperalgesia 01/01/2023 - "Continuous intrathecal administration of CB2R agonist PM226 attenuated mechanical and cold hyperalgesia in rats and prevented the transition of microglia to the proinflammatory stage. "
3.	Demyelinating Diseases (Demyelinating Disease) 01/01/2016 - "The most promising compound [43 (PM226)], a selective and potent CB2 agonist isoxazole derivative, was tested in the acute phase of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a well-established animal model of primary progressive multiple sclerosis. "

Related Drugs and Biologics

1.	Isoxazoles